October NME User Fee Lineup Includes Solifenacin, Darifenacin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has at least 28 pending applications with user fee deadlines in October, including seven NMEs and one new biologic.
You may also be interested in...
Duloxetine Drug Interactions Are Issue For Yentreve, But Not For Cymbalta
Review documents for Cymbalta note a difference in opinion regarding the significance of drug interactions between FDA’s review divisions for the two duloxetine indications – major depressive disorder and stress urinary incontinence (under the trade name Yentreve).
Second Cymbalta "approvable"
Lilly's serotonin/norepinephrine reuptake inhibitor Cymbalta (duloxetine) is "approvable" Sept. 29. FDA's second approvable letter for the antidepressant cites manufacturing issues at Indianapolis site. Duloxetine has also been deemed approvable for stress urinary incontinence (1Pharmaceutical Approvals Monthly Sept. 1, 2003, p. 6)...
Second Cymbalta "approvable"
Lilly's serotonin/norepinephrine reuptake inhibitor Cymbalta (duloxetine) is "approvable" Sept. 29. FDA's second approvable letter for the antidepressant cites manufacturing issues at Indianapolis site. Duloxetine has also been deemed approvable for stress urinary incontinence (1Pharmaceutical Approvals Monthly Sept. 1, 2003, p. 6)...